Ann: IHL-42X patent update & open label extension study approval, page-177

Hey TV,

It's not about trust (although you should never fully trust any BOD in any company - some level of scepticism is always warranted) as I'm happy with how they've progressed everything to date.

I'm just trying to understand if they legitimately couldn't or if they just didn't want to yet. Which could be a simple an answer as this trial is super important for IHLs success - so they want FULL results before releasing anything to market meanintlg they are irrefutable (either way). Which is what I'm leaning towards

That being said, I've read the announcement and what you've highlighted and it doesn't completely answer my secondary question about blinding being separate between unis or not. They only state UWA is dosing still vs. both still going. So if dosing / trial is completed in Vic, surely one set of results is ready. Anyways, this was for my personal knowledge around clinical trials and how they're structured.